SynthesisScientific reports2023
Risk factors and 26-years worldwide prevalence of endoscopic erosive esophagitis from 1997 to 2022: a meta-analysis.
Synthesis in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Vonoprazan Versus Lansoprazole in the Healing and Maintenance Phase of Erosive Esophagitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Digestive diseases and sciences · 2025Pooled it
- The association between Helicobacter pylori infection and diabetes mellitus: an updated meta-analysis of 45 case-control studies.Journal of health, population, and nutrition · 2025Pooled it
- Relationship between metabolic syndrome-related parameters and endoscopic classification of gastroesophageal reflux disease: a Japanese health checkup cohort study.Esophagus : official journal of the Japan Esophageal Society · 2026Article
- Fexuprazan and Esomeprazole in Patients with Disorders Associated with Acid Reflux: A Comprehensive Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2026Review
- Impact of kimura-takemoto atrophy classification on first-lineFrontiers in medicine · 2026Article
- Esophageal Perforation in Zollinger-Ellison Syndrome: A Scoping Review of Management and Outcomes.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Tegoprazan Versus Proton Pump Inhibitors for Erosive Esophagitis: A Meta-Analysis of Noninferiority Randomized Controlled Trials.JGH open : an open access journal of gastroenterology and hepatology · 2025Review
- Erosive Esophagitis Unveiled: A Retrospective Study of Epidemiology and Endoscopic Findings in Qassim, Saudi Arabia.Cureus · 2025Article
- Increased Prevalence of Barrett's Esophagus in Taiwan: A Prospective Multicenter Study.Journal of gastroenterology and hepatology · 2025Article
- Review Article: Individualised Management of Reflux-Like Symptoms-Strategies Beyond Acid Suppression.Alimentary pharmacology & therapeutics · 2025Review
- Prevalence and Risk Factors of Gastroesophageal Reflux Disease in Patients with Dyspeptic and Reflux Symptoms: An Endoscopy-Based Prospective Study from Al Khobar, Saudi Arabia.Journal of epidemiology and global health · 2025Observational
- Accuracy of COuGH RefluX Score as a Predictor of Gastroesophageal Reflux Disease (GERD) in Mexican Patients with Chronic Laryngopharyngeal Symptoms: A Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2025Article
- Medication use and risk of reflux oesophagitis.BMJ open gastroenterology · 2024Article
- The causal relationship between COVID-19 and ten esophageal diseases: a study utilizing Mendelian randomization.Frontiers in medicine · 2024Article
- Hiatal hernia: risk factors, and clinical and endoscopic aspects in gastroscopy.Gastroenterology report · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Erosive esophagitis (EE) is the part of gastroesophageal reflux disease (GERD) spectrum and may progress to esophageal adenocarcinoma. Due to its progressivity and unclear prevalence, we aim to identify the factors contributing in EE to decide the need for further examination. We performed a PRISMA 2020-based systematic search through PubMed and other resources up to June 2, 2022. Study quality was assessed using the Newcastle-Ottawa Scale (NOS). The odds ratio (OR) of each factor and worldwide prevalence of EE were measured. There are 114 observational studies included with a total of 759,100 participants. Out of 29 factors, the significant risk factors are age ≥ 60 y.o. (OR 2.03 [1.81-2.28]), White/Caucasian (OR 1.67 [1.40-1.99]), unmarried (OR 1.08 [1.03-1.14]), having GERD ≥ 5 years (OR 1.27 [1.14-1.42]), general obesity (OR 1.78 [1.61-1.98]), central obesity (OR 1.29 [1.18-1.42]), diabetes mellitus (DM) (OR 1.24 [1.17-1.32]), hypertension (OR 1.16 [1.09-1.23]), dyslipidemia (OR 1.15 [1.06-1.24]), hypertriglyceridemia (OR 1.42 [1.29-1.57]), hiatal hernia (HH) (OR 4.07 [3.21-5.17]), and non-alcoholic fatty liver disease (NAFLD) (OR 1.26 [1.18-1.34]). However, H. pylori infection (OR 0.56 [0.48-0.66]) and atrophic gastritis (OR 0.51 [0.31-0.86]) are protective towards EE. This study demonstrates that age, ethnicity, unmarried, long-term GERD, metabolic diseases, HH, and NAFLD act as risk factors for EE, whereas H. pylori infection and atrophic gastritis act as protective factors. These findings may enable a better understanding of EE and increase greater awareness to address its growing burden.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.